Loading…
Men and Families Health Care Act of 2009
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
37pct
1d open
vs 6,490 other HR bills in the 111th — cohort avg 44d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2010 · fourth_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support Medicare reimbursement for Provenge to treat prostate cancer. Support the most stringent and rigorous testing of biosimilars that would or could be used as replacements for the original, innovator biologic drugs. Support the Council for American Medical Innovation comments to The National Commission on Fiscal Responsibility and Reform regarding the continuing need for spending to promote medical innovation to save lives and money. Support the Partnership to Fight Chronic Disease response to the Agency for Healthcare Research and Quality request for feedback on the National Quality Strategy and Plan development in regards to the Affordable Care Act.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $76,368 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
2010 · fourth_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2010 · third_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2010 · fourth_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support Medicare reimbursement for Provenge to treat prostate cancer. Support the most stringent and rigorous testing of biosimilars that would or could be used as replacements for the original, innovator biologic drugs. Support the Council for American Medical Innovation comments to The National Commission on Fiscal Responsibility and Reform regarding the continuing need for spending to promote medical innovation to save lives and money. Support the Partnership to Fight Chronic Disease response to the Agency for Healthcare Research and Quality request for feedback on the National Quality Strategy and Plan development in regards to the Affordable Care Act.
Client expense: Not reported · Firm income: $13,310
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
2010 · third_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.
Client expense: $176,190 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2010 · third_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2010 · third_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.
2010 · second_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.
2010 · second_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2010 · second_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.
2010 · first_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.
Client expense: $175,137 · Firm income: Not reported
2010 · first_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.
Client expense: Not reported · Firm income: $12,701
2010 · first_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Protection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2010 · first_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.
Client expense: Not reported · Firm income: $25,403
2009 · fourth_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Oppose efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs
Client expense: $164,909 · Firm income: Not reported
2009 · fourth_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Protection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
2009 · fourth_quarter · Health Issues
H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Oppose efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs
Client expense: Not reported · Firm income: $26,618
2009 · third_quarter · Health Issues
S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Protection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
| Democratic |
| CA |
| Joe Sestak | Democratic | PA |
| John Tanner | Democratic | TN |
| Tim Murphy | Republican | PA |
Client expense: Not reported · Firm income: $13,695
Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Client expense: $172,523 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Client expense: Not reported · Firm income: $14,520
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office